FDA Advisory Panel Backs Leqembi for Alzheimer's Treatment

Psychiatrist.com·Jun 13

This story is reported by Psychiatrist.com. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug (Published 2024)

The New York Times·Jun 10

2

FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug

BioPharma Dive·Jun 9

3

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations

NPR·Jun 10

4

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Biogen·Jun 9

5

FDA advisers back Alzheimer's drug that can slow disease

PBS·Jun 10

6

FDA panel backs new Alzheimer’s drug, despite risks and uncertainties

Science | AAAS·Jun 11

7

Will New FDA Rules Help Dial Back Expedited Drugs?

Undark Magazine·Apr 12

8

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

NeurologyLive·Jul 6